Influence of 516G>T Polymorphisms at the Gene Encoding the CYP450-2B6 Isoenzyme on Efavirenz Plasma Concentrations in HIV-Infected Subjects

• Published in: Clinical infectious diseases Vol. 40; no. 9; pp. 1358 - 1361
• Main Authors: Rodriguez-Novoa, Sonia, Barreiro, Pablo, Rendón, Ana, Jiménez-Nacher, Inmaculada, González-Lahoz, Juan, Soriano, Vincent
• Format: Journal Article
• Language: English
• Published: Chicago, IL The University of Chicago Press 01.05.2005; University of Chicago Press; Oxford University Press
• Subjects: Adult; Antibiotics. Antiinfectious agents. Antiparasitic agents; Antiretrovirals; Antiviral agents; Antivirals; Benzoxazines; Biological and medical sciences; Cytochrome P-450 Enzyme System - genetics; Cytochromes; Drug therapy; Female; Genes; Genomics; Genotype; Genotype & phenotype; Genotypes; Heterozygote; HIV; HIV Infections - blood; HIV Infections - drug therapy; HIV Infections - genetics; HIV/AIDS; Homozygote; Human immunodeficiency virus; Human viral diseases; Humans; Infectious diseases; Isoenzymes - genetics; Liver; Male; Medical sciences; Medical treatment; Medical treatment failures; Metabolism; Middle Aged; Oxazines - adverse effects; Oxazines - blood; Oxazines - pharmacokinetics; Pharmacokinetics; Pharmacology. Drug treatments; Plasma; Polymorphism, Single Nucleotide; Viral diseases; Viral diseases of the lymphoid tissue and the blood. Aids; Immunopathology; Antiretroviral agent; Benzoxazine derivatives; RNA-directed DNA polymerase; Acetylenic compound; Enzyme; Non nucleoside compound; Transferases; Enzyme inhibitor; AIDS; Concentration; Immune deficiency; Efavirenz; Blood plasma; Infection; Nucleotidyltransferases; Gene; Reverse transcriptase inhibitor; Viral disease; Antiviral; Polymorphism
• ISSN: 1058-4838; 1537-6591; 1537-6591
• DOI: 10.1086/429327

We examined 516G>T polymorphisms at the gene encoding the cytochrome P450 in 100 human immunodeficiency virus–" ALIGN="BASELINE">positive subjects who were receiving efavirenz (EFV). Elevated plasma EFV concentrations were found in 40% of subjects with the polymorphic homozygous genotype and 19% of subjects with the heterozygous genotype. Conversely, 20% of subjects with the wild-type genotype had subtherapeutic concentrations of EFV. CYP2B6-516 genotyping may help to identify subjects who have plasma EFV concentrations that are outside of the therapeutic range.